Investigación / Grupos de investigación

Área 3 Enfermedades Cardiovasculares

Grupo  3

Electrofisiología Cardíaca Celular

Publicaciones (105)

  • Tamargo, J; Caballero, R; Delpon, E.

    The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease

    EXPERT OPINION ON PHARMACOTHERAPY. 2021; 22(10): 1319-1341 Nº de citas: 2 [doi:10.1080/14656566.2021.1891223]

  • Martín García A; Mitroi C; Mazón Ramos P; García Sanz R; Virizuela JA; Arenas M; Egocheaga Cabello I; Albert D; Anguita Sánchez M; Arrarte Esteban VI; Ayala de la Peña F; Bonanand Lozano C; Castro A; Castro Fernández A; Córdoba R; Cosín-Sales J; Chaparro-Muñoz M; Dalmau R; Drak Hernández Y; Deiros Bronte L; Díez-Villanueva P; Escobar Cervantes C; Fernández Redondo C; García Rodríguez E; Lozano T; Marco Vera P; Martínez Monzonis A; Mesa D; Oristrell G; Palma Gámiz JL; Pedreira M; Reinoso-Barbero L; Rodríguez I; Serrano Antolín JM; Toral B; Torres Royo L; Velasco Del Castillo S; Vicente-Herrero T; Zatarain-Nicolás E; Tamargo J; López Fernández T.

    Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC.

    REVISTA ESPANOLA DE CARDIOLOGIA. 2021; 74(5): 438-448 [doi:10.1016/j.rec.2020.11.020]

  • Garcia, AM; Mitroi, C; Ramos, PM; Sanz, RG; Virizuela, JA; Arenas, M; Cabello, IE; Albert, D; Sanchez, MA; Esteban, VIA; de la Pena, FA; Lozano, CB; Castro, A; Fernandez, AC; Cordoba, R; Cosin-Sales, J; Chaparro-Munoz, M; Dalmau, R; Hernandez, YD; Bronte, LD; Diez-Villanueva, P; Cervantes, CE; Redondo, CF; Rodriguez, EG; Lozano, T; Vera, PM; Monzonis, AM; Mesa, D; Oristrell, G; Gamiz, JLP; Pedreira, M; Reinoso-Barbero, L; Rodriguez, I; Antolin, JMS; Toral, B; Royo, LT; del Castillo, SV; Vicente-Herrero, T; Zatarain-Nicolas, E; Tamargo, J; Fernandez, TL.

    Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC

    REVISTA ESPANOLA DE CARDIOLOGIA. 2021; 74(5): 438-448 Nº de citas: 24 [doi:10.1016/j.recesp.2020.11.014]

  • Gonzalez-Juanatey, JR; Tamargo, J; Torres, F; Weisser, B; Oudovenko, N.

    Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents?

    REVISTA ESPANOLA DE CARDIOLOGIA. 2021; 74(1): 51-58 Nº de citas: 15 [doi:10.1016/j.recesp.2019.11.021]

  • Tamargo, J; Rosano, G.

    Low quality of some generic cardiovascular medicinal products represents a matter for growing concern

    European Heart Journal-Cardiovascular Pharmacotherapy. 2020; 6(3): 176-187 Nº de citas: 5 [doi:10.1093/ehjcvp/pvz037]

  • Tinaquero, D; Crespo-Garcia, T; Utrilla, RG; Nieto-Marin, P; Gonzalez-Guerra, A; Rubio-Alarcon, M; Camara-Checa, A; Dago, M; Matamoros, M; Perez-Hernandez, M; Tamargo, M; Cebrian, J; Jalife, J; Tamargo, J; Bernal, JA; Caballero, R; Delpon, E; ITACA Investigators.

    The p.P888L SAP97 polymorphism increases the transient outward current (I-to,I-f) and abbreviates the action potential duration and the QT interval

    Scientific Reports. 2020; 10(1): Nº de citas: 8 [doi:10.1038/s41598-020-67109-z]

  • Savarese, G; Reiner, MF; Uijl, A; D'Amario, D; Agewall, S; Atar, D; Baumgartner, I; Borghi, C; De Carlo, M; Drexel, H; Kaski, JC; Kjeldsen, KP; Kucher, N; Lund, LH; Niessner, A; Semb, AG; Schmidt, TA; Sulzgruber, P; Tamargo, J; Vitale, C; Wassmann, S; Aboyans, V; Lewis, BS.

    Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases

    European Heart Journal-Cardiovascular Pharmacotherapy. 2020; 6(2): 86-93 Nº de citas: 31 [doi:10.1093/ehjcvp/pvz036]

  • Tamargo, J.

    Treatment of Coronavirus Disease 2019: Shooting in the Dark

    EUROPEAN CARDIOLOGY REVIEW. 2020; 15: Nº de citas: 2 [doi:10.15420/ecr.2020.21]

  • Haller, PM; Sulzgruber, P; Kaufmann, C; Geelhoed, B; Tamargo, J; Wassmann, S; Schnabel, RB; Westermann, D; Huber, K; Niessner, A; Gremmel, T.

    Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis

    European Heart Journal-Cardiovascular Pharmacotherapy. 2019; 5(4): 226-236 Nº de citas: 37 [doi:10.1093/ehjcvp/pvz021]

  • Ruilope, LM; Ruiz-Hurtado, G; Barderas, MG; de la Cruz, JJ; Lucia, A; de la Sierra, A; Gorostidi, M; Vinyoles, E; Segura, J; Solis, J; Arribas, F; Garcia-Puig, J; Tamargo, J; O'Brien, E; Volpe, M; Whelton, PK; Williams, B; Banegas, JR.

    Frequency and Prognosis of Treated Hypertensive Patients According to Prior and New Blood Pressure Goals Post Hoc Analysis of the Spanish Ambulatory Blood Pressure Monitoring Registry

    HYPERTENSION. 2019; 74(1): 130-136 Nº de citas: 11 [doi:10.1161/HYPERTENSIONAHA.119.12921]

  • Tamargo, J; Caballero, R; Delpon, E.

    Pharmacotherapy for hypertension in pregnant patients: special considerations

    EXPERT OPINION ON PHARMACOTHERAPY. 2019; 20(8): 963-982 Nº de citas: 7 [doi:10.1080/14656566.2019.1594773]

  • Nieto-Marin, P; Jimenez-Jaimez, J; Tinaquero, D; Alfayate, S; Utrilla, RG; del Rey, MDRV; Perin, F; Sarquella-Brugada, G; Monserrat, L; Brugada, J; Tercedor, L; Tamargo, J; Delpon, E; Caballero, R.

    Digenic Heterozigosity in SCN5A and CACNA1C Explains the Variable Expressivity of the Long QT Phenotype in a Spanish Family

    REVISTA ESPANOLA DE CARDIOLOGIA. 2019; 72(4): 324-332 Nº de citas: 9 [doi:10.1016/j.rec.2018.03.012]

  • Tamargo, J; Caballero, R; Delpon, E.

    New drugs in preclinical and early stage clinical development in the treatment of heart failure

    EXPERT OPINION ON INVESTIGATIONAL DRUGS. 2019; 28(1): 51-71 Nº de citas: 14 [doi:10.1080/13543784.2019.1551357]

  • Sanchez, M; Romero, M; Gomez-Guzman, M; Tamargo, J; Perez-Vizcaino, F; Duarte, J.

    Cardiovascular Effects of Flavonoids

    CURRENT MEDICINAL CHEMISTRY. 2019; 26(39): 6991-7034 Nº de citas: 54 [doi:10.2174/0929867326666181220094721]

  • Tamargo, J.

    Sodium-glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments

    EUROPEAN CARDIOLOGY REVIEW. 2019; 14(1): 23-32 Nº de citas: 47 [doi:10.15420/ecr.2018.34.2]

  • Vonbank, A; Drexel, H; Agewall, S; Lewis, BS; Dopheide, JF; Kjeldsen, K; Ceconi, C; Savarese, G; Rosano, G; Wassmann, S; Niessner, A; Schmidt, TA; Saely, CH; Baumgartner, I; Tamargo, J.

    Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review

    European Heart Journal-Cardiovascular Pharmacotherapy. 2018; 4(4): 230-236 Nº de citas: 42 [doi:10.1093/ehjcvp/pvy028]

  • Perez-Hernandez, M; Matamoros, M; Alfayate, S; Nieto-Marin, P; Utrilla, RG; Tinaquero, D; de Andres, R; Crespo, T; Ponce-Balbuena, D; Willis, BC; Jimenez-Vazquez, EN; Guerrero-Serna, G; da Rocha, AM; Campbell, K; Herron, TJ; Diez-Guerra, FJ; Tamargo, J; Jalife, J; Caballero, R; Delpon, E.

    Brugada syndrome trafficking-defective Nav1.5 channels can trap cardiac Kir2.1/2.2 channels

    Jci Insight. 2018; 3(18): Nº de citas: 40 [doi:10.1172/jci.insight.96291]

  • Rosano, GMC; Tamargo, J; Kjeldsen, KP; Lainscak, M; Agewall, S; Anker, SD; Ceconi, C; Coats, AJS; Drexel, H; Filippatos, G; Kaski, JC; Lund, L; Niessner, A; Ponikowski, P; Savarese, G; Schmidt, TA; Seferovic, P; Wassmann, S; Walther, T; Lewis, BS.

    Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

    European Heart Journal-Cardiovascular Pharmacotherapy. 2018; 4(3): 180-188 Nº de citas: 158 [doi:10.1093/ehjcvp/pvy015]